Premium
Pharmacokinetic profile of a single dose of an oral pradofloxacin suspension administered to eastern long‐necked turtles ( Chelodina longicollis )
Author(s) -
Taylor Emily,
Trott Darren J.,
Kimble Benjamin,
Xie Shangzhe,
Govendir Merran,
McLelland David J.
Publication year - 2021
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/jvp.12933
Subject(s) - pharmacokinetics , cmax , cats , oral administration , veterinary medicine , biology , withdrawal time , pharmacology , zoology , medicine , colorectal cancer , colonoscopy , cancer
The pharmacokinetics of fluoroquinolones in chelonians are well described but this does not extend to pradofloxacin, a broad‐spectrum veterinary fluoroquinolone available as an oral suspension for cats and dogs. The aim of this study was to investigate the single‐dose pharmacokinetic profile of pradofloxacin oral suspension at 7.5 mg/kg in eastern long‐necked turtles ( Chelodina longicollis ). Eight treated turtles were sampled at multiple time points up to 168 hr. Plasma concentrations were measured using high‐performance liquid chromatography. Pradofloxacin was quantifiable for up to 48 hr after drug administration. The T max (9.0 hr) and T ½ to 48 hr (13.16 hr) were longer, and the C max (0.2 μg/ml) and AUC 0‐24 (2.2 hr*μg/ml) lower, than previously reported in cats and dogs. Pradofloxacin was measurable in tank water samples for up to 48 hr. No adverse effects were observed in six turtles administered 7.5 mg/kg sid for 7 days. Using mammalian MIC data, the AUC 0‐24 /MIC ratios for a range of bacterial isolates suggest that this dose of pradofloxacin in turtles is unlikely to be effective against many bacterial pathogens.